Peripheral Cystoid Degeneration Finding Using Intraoperative Optical Coherence Tomography in Rhegmatogenous Retinal Detachment

Abstract

Purpose

The interaction between the peripheral vitreous and retina is closely associated with the pathogenesis of rhegmatogenous retinal detachment (RRD). This study was conducted to examine the peripheral vitreous and retina in patients with RRD using intraoperative optical coherence tomography (iOCT).

Methods

This retrospective study included 50 eyes of 50 patients (mean age 59.42 ± 10.80 years) that underwent vitrectomy using iOCT for treating RRD at the Yamagata University Hospital between September 2015 and September 2016. Each patient underwent 25-gauge pars plana vitrectomy that was performed by a single surgeon. During vitreous shaving with ocular indentation, the iOCT findings of the peripheral vitreous and retina were recorded and analyzed postoperatively.

Results

In all patients, iOCT was able to detect the peripheral retina and vitreous around the vitreous base. Peripheral cystoid degeneration was detected on the peripheral retina of 27 eyes (54%). Furthermore, cystoid degeneration was detected around the retinal tear (5 patients), at the detached retinal area (8 patients), and at the attached retinal area (14 patients).

Conclusion

iOCT enabled the evaluation of peripheral cystoid degeneration in patients with RRD. Cystoid degeneration might be associated with the pathogenesis of RRD.

Keywords:

• peripheral retinal degeneration
• rhegmatogenous retinal detachment
• cystoid degeneration
• intraoperative optical coherence tomography

Acknowledgments

The Annual Meeting of the Association for Research in Vision and Ophthalmology, Honolulu (USA), April 29 to May 3, 2018.

Disclosure

Mr Koichi Nishitsuka reports personal fees from Santen, RE MEDICAL, INC., Carl Zeiss, Alcon, NOVARTIS, Kowa Company. Ltd., Johnson & Johnson, SENJU Pharmaceutical Co., Ltd., SANWA KAGAKU KENKYUSHO CO., LTD., and HOYA, outside the submitted work. Mr Hidetoshi Yamashita reports grants from Atsuzawa Prosthesis Co., Ltd., Alcon Japan Ltd., Santen Pharmaceutical Co., Ltd., Eisai Co., Ltd., SENJU PHARMACEUTICAL Co., Ltd., B.L.J Company, Ltd., Bayer Yakuhin, Ltd., AMO Japan, NOVARTIS Pharma Japan, Trust Medical Co., Ltd., and Taisho Pharma Japan, outside the submitted work. The authors report no other conflicts of interest in this work.

Additional information

Funding

This work was supported by JSPS KAKENHI Grant Number JP25462704.